Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Reader Login
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   1996| March  | Volume 17 | Issue 1  
    Online since May 30, 2009

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Rhabdomyosarcoma in children :clinical features and results of an aggressive chemotherapy regimen.
G Kapoor, N Raje, S Vaidya, S Rao, CN Nair, PA Kurkure, SC Pande, DV Swaroop, RK Deshpande, SH Advani
March 1996, 17(1):32-39
The aim of the present article was to study the pattern of pediatric rhabdomyosarcoma and the results of an aggressive chemotherapy regimen, in a setting where radical surgery may not always be feasible. Twenty seven consecutive patients. 0-20 years of age, registered at the Tata Memorial Hospital between March 1989 and march 1993 were evaluated. All patients were treated with multi-modality approach. A significantly large number of patients presented with parameningeal head and neck disease(30)and extremity lesions(22). In addition most patients had advanced disease(96 had IRS clinical group III or IV disease)at presentation. Complete response rate was 67 and overall and disease free survival at the end of 2 years was 42.5 and 29. Loco-regional relapse or disease progression was the main cause of mortality. Myelosuppression was the major toxicity observed with this chemotherapy schedule.
[ABSTRACT]   Full text not available   
  743 0 -
Chromosome sensitivity studies in patients with down syndrome.
RK Patel, RJ Jaiju, SR Bakshi, AH Trivedi, UM Rawal, KH Jani, SH Bhachech, DB Balar
March 1996, 17(1):23-31
Spontaneous and Bleomycin(BLM) induced chromosome aberration frequencies were assessed in 20 Down syndrome patients and 20 normal controls. Peripheral blood lymphocyte cultures were exposed to BLM during the last 5 hrs (late S-G2phase) of incubation. The findings showed significantly higher rates of chromatid-type aberrations(CA/cell)as well as chromatid-type + chromosome-type aberrations(TA/cell) in untreated cells as well as BLM-treated cells of the Down syndrome patients compared to normal individuals. After excluding gaps from CA/cell and TA/cell, only spontaneous rates were higher among DS patients. Whereas BLM induced aberrations without gap were comparable among both the groups of individual. Results of the present study support the hypothesis that individuals with Down syndrome have a high rate of spontaneous chromosomal aberrations which may contributing to their higher risk of developing cancer.
[ABSTRACT]   Full text not available   
  694 0 -
Malignant mesothelioma of the tunica vaginalis testis :a case report and review of literature.
V Raina, NA Jadeja, R Safaya, NP Gupta
March 1996, 17(1):45-49
We present an elderly man who was diagnosed to have malignant mesothelioma of tunica vaginalis of testis. Because of the rarity of the tumour, the diagnosis was delayed and appropriate steps at early stages were not taken. This resulted in local recurrence. Inspite of radical surgery the tumour recurred. Response to chemotherapy was poor. Only 37 cases have reported till date. Radical surgery seems to be the treatment of choice. Because of its rarity, the information on the role of radiotherapy and chemotherapy is scanty.
[ABSTRACT]   Full text not available   
  631 0 -
Pulmonary blastoma :a case report and review of chemotherapy experience.
A Sharma, L Kumar, MS Sandhu, R Kamble, S Sharma
March 1996, 17(1):50-56
Pulmonary blastoma is a rare primary malignant lung neoplasm, compared of immature mesenchymal and or epithelium which is morphologically similar to fetal lung tissue. Till date, less than 100 cases have been reported. The rarity of tumour has precluded focussed clinical trials hence no consensus exists regarding treatment of these patients. Most people have used surgery as the primary modality but both chemotherapy and radiation therapy have been used for adjuvant and for metastatic disease. The patient described here presented with secondaries to the contralateral lung, an unusual presentation. Following diagnostic thoracotomy, he has been given four cycles of chemotherapy comprising of Cisplatin and Etoposide to which he has shown good partial response. We conclude that cisplatin based chemotherapy is effective in pulmonary blastoma, however,its role needs to be further evaluated.
[ABSTRACT]   Full text not available   
  625 0 -
Unusual second malignancies in childhood retinoblastoma.
M Gera, B Gera, SH Advani, Gera Manish
March 1996, 17(1):40-44
Patients with heritable retinoblastoma have a substantial risk of developing second malignant tumor. The incidence of second malignant tumors increases with time. The commonest second malignancy is usually osteosarcoma. The Rb gene provides a genetic basis for this observation, as there is a risk of developing a second malignancy among children with germline Rb mutations irrespective of treatment. Here we report two unusual second malignancies-a pleomophic spindle cell squamous carcinoma and a peripheral nerve sheath sarcoma arising in treated patients of bilateral and unilateral retinoblastoma respectively.
[ABSTRACT]   Full text not available   
  615 0 -
Tumor markers in clinical oncology.
JM Bhatavdekar, DD Patel, N Ghosh
March 1996, 17(1):8-22
The association of biologic markers with cancer has been recognised for many decades. Tumor markers are substances that can be measured quantitatively by immunochemical or biochemical means in body fluids or tissues to detect a cancer and possibly the organ where it resides, to establish the exten of tumor burden before treatment, and to monitor the response to therapy. These include tumor associated antigens, specific proteins, metabolites, and oncogenes and oncogene products. The most commonly used tumor markersare:carcinoembryonic antigen(CEA), alpha feto-protein(AFP), human chorionic goandotrophin(beta HCG), prostate specific antigen(PSA) and CA 125.
[ABSTRACT]   Full text not available   
  546 0 -
Cancer in the infants.
BJ Parikh, PM Shah, A Anand, J Parikh Bharat
March 1996, 17(1):6-7
Full text not available   
  294 0 -
Late effects of childhood cancer therapy.
P Kusumakumari
March 1996, 17(1):1-5
Full text not available   
  263 0 -
  Feedback 
  Subscribe